Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106
Kymera Therapeutics Presented New Preclinical Data For KT-579 Demonstrating Disease-modifying Activity In An Inflammatory Bowel Disease Model, KT-579 Phase 1 Healthy Volunteer Trial Ongoing, With Data Expected In 2H26
Kymera Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat
Kymera Therapeutics Q1 EPS $(0.71) Beats $(0.88) Estimate, Sales $34.365M Beat $8.614M Estimate
The FDA Grants Fast Track Designation For Kymera Therapeutics' KT-621 For Moderate to Severe Asthma
Reported Saturday, Kymera's Phase 1b BroADen Data Shows KT-621 Delivers Robust Type 2 Inflammatory Biomarker Reductions And Meaningful Clinical Improvements In Moderate-To-Severe Atopic Dermatitis
Kymera Therapeutics (KYMR) to Present Phase 1b BroADen Trial Data for KT-621 at AAD 2026
Nextech Trims Kymera at a Recent High — think Foolishly before acting.
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Kymera Therapeutics To Present Eczema Drug Trial Results At Major Dermatology Conference
UBS Maintains Buy on Kymera Therapeutics, Raises Price Target to $128
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $120
Stephens & Co. Maintains Overweight on Kymera Therapeutics, Raises Price Target to $100
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.